文献速递泌尿男性生殖肿瘤

基因组分类器增强病理特征在前列腺癌患者中识别辅助放疗最佳候选者的作用:多变量预后模型的开发与内部验证

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
PubMed 文献 · J Clin Oncol · 2017-03-28

研究纳入1990至2010年间在美国四家学术中心接受根治性前列腺切除术的512例前列腺癌患者,开发并内部验证了结合Decipher评分与常规临床病理特征的风险分层工具。中位随访8.3年,10年临床复发率在辅助放疗组为4.9%,初始观察组为17.4%(P<.001)。在具有两个及以上风险因素的患者中,辅助放疗与临床复发率降低相关(10年临床复发率10.1% vs 42.1%,P=.012),而在少于两个风险因素的患者中无显著差异(P=.18)。

要点

  • 病理T3b/T4期、Gleason评分8-10、淋巴结侵犯和Decipher评分>0.6是临床复发的独立预测因素(均P<.01)。
  • 具有两个及以上风险因素的患者中,辅助放疗组10年临床复发率10.1%,初始观察组42.1%(P=.012)。
  • 少于两个风险因素的患者中,辅助放疗与初始观察的临床复发率无显著差异(P=.18)。

核心结论

  • 使用新模型指示辅助放疗可能减少过度治疗、降低不必要的不良反应,并降低从该治疗中获益的部分患者(本队列中约25%具有侵袭性病理特征的患者)的临床复发风险。

研究设计与样本

  • 队列纳入1990至2010年间在美国四家学术中心之一接受根治性前列腺切除术的512例前列腺癌患者,所有患者具有≥pT3a疾病、手术切缘阳性或病理淋巴结侵犯。
  • 采用多变量Cox回归分析检验包括Decipher评分在内的可用预测因素与临床复发之间的关系,并据此开发新的风险分层工具。
  • 研究遵循多变量预后或诊断个体预后模型透明报告指南进行预后模型开发。

主要发现

  • 总体有21.9%的患者接受了辅助放疗。
  • 删失患者的中位随访时间为8.3年。
  • 接受辅助放疗与初始观察的患者10年临床复发率分别为4.9%与17.4%(P<.001)。
  • 病理T3b/T4期、Gleason评分8-10、淋巴结侵犯和Decipher评分>0.6是临床复发的独立预测因素(均P<.01)。
  • 风险因素累计数为0、1、2和3至4个的患者分别占46.5%、28.9%、17.2%和7.4%;在具有两个及以上风险因素的患者中,辅助放疗与临床复发率降低相关(10年临床复发率辅助放疗组10.1% vs 初始观察组42.1%;P=.012),而在少于两个风险因素的患者中无显著差异(P=.18)。

关键数值与推荐

  • 风险因素包括病理T3b/T4期、Gleason评分8-10、淋巴结侵犯和Decipher评分>0.6。
  • 辅助放疗组10年临床复发率4.9% vs 初始观察组17.4%(P<.001)。
  • 具有两个及以上风险因素的患者中,辅助放疗组10年临床复发率10.1% vs 初始观察组42.1%(P=.012)。
  • 少于两个风险因素的患者中,辅助放疗与初始观察比较P=.18。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Despite documented oncologic benefit, use of postoperative adjuvant radiotherapy (aRT) in patients with prostate cancer is still limited in the United States. We aimed to develop and internally validate a risk-stratification tool incorporating the Decipher score, along with routinely available clinicopathologic features, to identify patients who would benefit the most from aRT. Patient and Methods Our cohort included 512 patients with prostate cancer treated with radical prostatectomy at one of four US academic centers between 1990 and 2010. All patients had ≥ pT3a disease, positive surgical margins, and/or pathologic lymph node invasion. Multivariable Cox regression analysis tested the relationship between available predictors (including Decipher score) and clinical recurrence (CR), which were then used to develop a novel risk-stratification tool. Our study adhered to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis guidelines for development of prognostic models. Results Overall, 21.9% of patients received aRT. Median follow-up in censored patients was 8.3 years. The 10-year CR rate was 4.9% vs. 17.4% in patients treated with aRT versus initial observation ( P < .001). Pathologic T3b/T4 stage, Gleason score 8-10, lymph node invasion, and Decipher score > 0.6 were independent predictors of CR (all P < .01). The cumulative number of risk factors was 0, 1, 2, and 3 to 4 in 46.5%, 28.9%, 17.2%, and 7.4% of patients, respectively. aRT was associated with decreased CR rate in patients with two or more risk factors (10-year CR rate 10.1% in aRT v 42.1% in initial observation; P = .012), but not in those with fewer than two risk factors ( P = .18). Conclusion Using the new model to indicate aRT might reduce overtreatment, decrease unnecessary adverse effects, and reduce risk of CR in the subset of patients (approximately 25% of all patients with aggressive pathologic disease in our cohort) who benefit from this therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dalela D, Santiago-Jiménez M, Yousefi K, et al. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. J Clin Oncol. 2017. PMID: 28350520. doi:10.1200/JCO.2016.69.9918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。